(Q57904791)

7

object named as

Meletios A. Dimopoulos

0 references

author name string

Aristotle Bamias

2

0 references

Vassiliki Koutsoukou

3

0 references

Eleni Efstathiou

4

0 references

Dimitra Gika

5

0 references

Christos A. Papadimitriou

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

6

0 references

language of work or name

English

0 references

publication date

March 2007

0 references

published in

Gynecologic Oncology

0 references

volume

104

0 references

issue

3

0 references

page(s)

580-585

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Second-line treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Review of gemcitabine-based combinations for platinum-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Gemcitabine-cisplatin: a schedule finding study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006

Management of platinum-sensitive recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.006